Under the terms of the agreement, Serenex will retain all rights to develop and commercialize evaluated molecules. The Hsp90 inhibitors being tested are synthetic small molecules discovered internally using Serenex’s proprietary chemoproteomics technology platform.
Richard Kent, president and CEO of Serenex, said: “The compounds that we will evaluate with CHDI are distinct from SNX-5422, our orally active Hsp90 inhibitor for oncology, and are specifically targeted for the treatment of CNS diseases.”